WallStreetZen

NYSE: BMY
Bristol Myers Squibb Co Stock

$62.00-0.11 (-0.18%)
Updated Sep 15, 2021
BMY Price
$62.00
Fair Value Price
N/A
Market Cap
$137.77B
52 Week Low
$56.75
52 Week High
$69.75
P/E
-27.68x
P/B
3.74x
P/S
3.36x
PEG
N/A
Dividend Yield
3.1%
Revenue
$44.38B
Earnings
-$5.08B
Gross Margin
75.9%
Operating Margin
-9.31%
Profit Margin
-11.4%
Debt to Equity
2.01
Operating Cash Flow
$13B
Beta
0.65
Next Earnings
Oct 27, 2021
Ex-Dividend
Sep 30, 2021
Next Dividend
Nov 1, 2021

Zen Score

High
Medium
Low
31
Industry average

Reasons for this score

BMY is good value based on its book value relative to its share price (3.74x), compared to the US Drug Manufacturers - General industry average (5.17x)
Valuation
BMY's Earnings (EBIT) of -$4.13B are insufficient to safely cover interest payments on company debt ($45.16B)
Financials
BMY's profit margin has decreased (-9.8%) in the last year from (-1.6%) to (-11.4%)
Financials

1 of 9

BMY News

Valuation

BMY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-27.68x
Industry
21.95x
Market
-8.74x

BMY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.74x
Industry
5.17x
BMY is good value based on its book value relative to its share price (3.74x), compared to the US Drug Manufacturers - General industry average (5.17x)
Valuation

BMY's financial health

Profit margin

Revenue
$11.7B
Net Income
$1.1B
Profit Margin
9%
BMY's Earnings (EBIT) of -$4.13B are insufficient to safely cover interest payments on company debt ($45.16B)
Financials
BMY's profit margin has decreased (-9.8%) in the last year from (-1.6%) to (-11.4%)
Financials

Assets to liabilities

Assets
$110.8B
Liabilities
$73.9B
Debt to equity
1.23
BMY's short-term assets ($29.16B) exceed its short-term liabilities ($18.99B)
Financials
BMY's long-term liabilities ($54.93B) exceed its short-term assets ($29.16B)
Financials
BMY's debt has increased relative to shareholder equity (2.01), over the past 5 years ago (1.19)
Financials
BMY's debt to equity ratio (2.01) is considered high
Financials

Cash flow

Operating
$3.1B
Investing
$180.0M
Financing
-$3.2B
BMY's operating cash flow ($12.77B) is sufficient to service the company's debt ($45.16B)
Financials

Bristol Myers Squibb Stock FAQ

What is Bristol Myers Squibb's quote symbol?

(NYSE: BMY) Bristol Myers Squibb trades on the NYSE under the ticker symbol BMY. Bristol Myers Squibb stock quotes can also be displayed as NYSE: BMY.

What is the 52 week high and low for Bristol Myers Squibb (NYSE: BMY)?

(NYSE: BMY) Bristol Myers Squibb's 52-week high was $69.75, and its 52-week low was $56.75. It is currently -11.11% from its 52-week high and 9.24% from its 52-week low.

How much is Bristol Myers Squibb stock worth today?

(NYSE: BMY) Bristol Myers Squibb currently has 2,222,113,553 outstanding shares. With Bristol Myers Squibb stock trading at $62.00 per share, the total value of Bristol Myers Squibb stock (market capitalization) is $137.77B.

Bristol Myers Squibb stock was originally listed at a price of $47.32 in Dec 31, 1997. If you had invested in Bristol Myers Squibb stock at $47.32, your return over the last 23 years would have been 31.04%, for an annualized return of 1.18%.

How much is Bristol Myers Squibb's stock price per share?

(NYSE: BMY) Bristol Myers Squibb stock price per share is $62.00 today (as of Sep 15, 2021).

What is Bristol Myers Squibb's Market Cap?

(NYSE: BMY) Bristol Myers Squibb's market cap is $137.77B, as of Sep 16, 2021.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bristol Myers Squibb's market cap is calculated by multiplying BMY's current stock price of $62.00 by BMY's total outstanding shares of 2,222,113,553.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.